Drug intelligence / Profile preview

IDP-233

Development stage: Preclinical
Lead developer: IDP Discovery Pharma
Modality: Modified Peptides → Peptides, Small Molecules

Overview

IDP-233 is a first-in-class ASCL1 inhibitor being developed by IDP Pharma for the treatment of neuroendocrine malignancies, including small cell lung cancer (SCLC) and neuroendocrine prostate cancer (nePC). ASCL1 (Achaete-Scute Complex-Like 1) is a transcription factor and an intrinsically disordered protein (IDP) that plays a critical role in the development and progression of neuroendocrine cancers. IDP-233 is a small molecule peptidomimetic designed using IDP Pharma's proprietary Intrametics™ technology platform, which enables the direct inhibition and cellular degradation of IDPs. The drug is currently in preclinical development, undergoing toxicology and formulation studies.

Targets

ASCL1 (Achaete-scute homolog 1)

Beyond the preview

Go deeper on IDP-233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP-233.

Explore the full profile